Sublobar resection versus ablation for stage I non-small-cell lung cancer: a meta-analysis

Table 1 Characteristics of the included studies

Study/year/country	Groups	Sample size	Male/female	Age (years)	Tumor size (mm)	FEV1/predicted (%)	CCMI	NOS
Alexander/2013/USA [10]	SR	28	12/16	74	NG	54	42.61	7
Alexander/2013/USA [10]	Ablation	56	24/32	78	NG	52	42.45	7
Ambrogi/2015/Italy [11]	SR	59	46/13	70	26	47	NG	8
Ambrogi/2015/Italy [11]	Ablation	62	45/17	76	23	49	NG	8
Hu/2020/China [12]	SR	155	103/52	78	25	71	4^a	8
Hu/2020/China [12]	Ablation	68	44/24	83	23	63	4^a	8
Iguchi/2020/Japan [13]	SR	193	101/92	67	16	NG	2.78^a	7
Iguchi/2020/Japan [13]	Ablation	38	22/16	75	22	NG	3.03^a	7
Kwan/2014/USA [14]	SR	69	36/33	NG	NG	NG	NG	6
Kwan/2014/USA [14]	Ablation	99	26/73	NG	NG	NG	NG	6
Safi/2015/Germany [15]	SR	42	27/15	70	19	69	6.2	8
Safi/2015/Germany [15]	Ablation	25	18/7	71	22	67	5.5	8
Zemlyak/2010/USA [16]	SR	25	9/16	66	NG	65	NG	7
Zemlyak/2010/USA [16]	Ablation	12	7/5	74	NG	64	NG	7
Zeng/2020/China [17]	SR	108	58/60	70.2	NG	NG	NG	7
Zeng/2020/China [17]	Ablation	108	44/64	68.1	NG	NG	NG	7

CCMI Charlson Comorbidity Index, SR sublobar resection, NG not given, NOS Newcastle–Ottawa scale
^aThe Charlson comorbidity index was significant lower in SR group

ISSN: 1749-8090